Oncolytics Biotech announced FDA feedback regarding the potential pivotal expansion of REO 033.
The study is evaluating pelareorep in second-line RAS-mutant MSS metastatic colorectal cancer, with the proposed regulatory strategy targeting potential accelerated approval and eventual full approval.
The story continues to develop.
News: https://finance.yahoo.com/healthcare/articles...00976.html Communicated Disclaimer: https://stockresearchtoday.com/oncy/